Product news from the 04/14/06 News Brief

Share this article:
FDA approved Alkermes and Cephalon’s Vivitrol (naltrexone for extended-release injectable suspension) for the treatment of alcohol dependence. The FDA has granted final approval to Dr. Reddy’s Laboratories’ Abbreviated New Drug Application for fexofenadine hydrochloride tablets, 30 mg, 60 mg and 180 mg. Fexofenadine hydrochloride is the generic equivalent of Sanofi-Aventis’ allergy drug Allegra. Dr. Reddy’s said it will begin the commercial marketing of this product immediately. Roche has filed for US approval of an expanded lung cancer indication for its Avastin colorectal cancer drug. Roche said studies show that Avastin is beneficial to patients with nonsquamous non-small-cell lung cancer, which accounts for 87% of all lung cancer cases in the US.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters